John C. Byrd, MD, is associate vice chancellor for cancer affairs, University of Pittsburgh, and director of UPMC Hillman Cancer Center, one of the nation’s premier National Cancer Institute-Designated Comprehensive Cancer Centers. In his role as director, Dr. Byrd will hold overall responsibility and authority for all aspects of the University of Pittsburgh and UPMC’s cancer-related basic, translational and clinical research, outreach and education. In addition, Dr. Byrd has been recommended for appointment to hold the Hillman Professorship of Oncology in Pitt’s Department of Medicine.
In a highly accomplished career spanning nearly three decades, Dr. Byrd has consistently excelled at cultivating environments where educational opportunities, research creativity, and rapid clinical translation of novel discoveries can thrive synergistically, a foundational tenet of the integrated research and patient care excellence we work daily to advance at the University of Pittsburgh and UPMC. Since 2021, he served as the Gordon and Helen Hughes Taylor Professor and chair of the Department of Internal Medicine at the University of Cincinnati (UC) College of Medicine as well as chief of internal medicine services at UC Health. He also served as a senior advisor to the University of Cincinnati Cancer Center, where he spearheaded the development and launch of the Blood Cancer Healing Center, the only blood cancer center in the nation where patients benefit from bench-to-bedside research and receive all their care—inpatient and outpatient, survivorship, integrative medicine and spiritual care—in one accessible building.
Dr. Byrd has more than 700 publications in the area of leukemia and experimental therapeutics research and runs a highly translational laboratory focused on chronic lymphocytic leukemia (CLL) and drug development in hematologic malignancies. He has been part of the successful development of multiple therapeutics for AML and CLL, holds 23 patents and serves on the scientific advisory boards of seven therapeutics companies, two of which he founded.
Prior to joining UC, Dr. Byrd served as senior advisor for cancer experimental therapeutics and Distinguished University Professor at The Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute. During his 20-year career with Ohio State, he also helped to build the Division of Hematology as its founding director.
He has been invited to present at more than 315 national and international scientific meetings and conferences, has authored 35 book chapters, and mentored more than 90 fellows, residents, PhD students, postdoctoral researchers and faculty members. His own research has been continually funded by industry, federal agencies and leading cancer philanthropies since 1997.
Dr. Byrd earned his MD from the University of Arkansas for Medical Sciences; completed his residency in internal medicine and a fellowship in hematology, oncology and bone marrow transplantation at the Walter Reed Army Medical Center; and completed his translational laboratory training at Johns Hopkins University.
- BA, Chemistry, Hendrix College, 1987
- MD, University of Arkansas for Medical Sciences, 1991
- Residency, Walter Reed Military Medical Center - National Capital Consortium
- Fellowship, Walter Reed Military Medical Center - National Capital Consortium
Education & Training
Rogers KA, Yan P, Flinn IW, Stephens DM, Kipps TJ, Larson SM, Martz L, Chen X, Wang H, Hopping E, Bundschuh R, Turkoglu A, Lozanski G, McGarry C, Acosta A, Sechaud R, Baldoni D, Chaudhury A, Whalen J, Hassounah NB, Orwitz N, Otero J, Woo J, Byrd JC. Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study. Clin Cancer Res. 2025 Dec 15;31(24):5145-5158. PMID: 41194375.
Stephens DM, Stewart C, Avruch L, Coombs CC, Danilov A, Hill B, Shadman M, Gerrie A, Jensen CE, Hoffmann M, Winter A, Ermann DA, Barr PM, O'Brien S, Koffman B, Byrd JC. Feasibility of Bruton's Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient Perspective. Clin Lymphoma Myeloma Leuk. 2025 Sep;25(9):e663-e667. PMID: 40483257.
Elgamal OA, Fobare S, Vibhute S, Mehmood A, Vroom DC, Johnson ML, Stearns B, Lerma JR, Truxall J, Stahl E, Carmichael B, Orwick SJ, Mims AS, Curran E, Santhanam R, Tridandapani S, Phelps MA, Xie Z, Coss CC, Baker SD, Patrick J, Ezzell JK, Rai J, Pan J, Rai SN, Stillwell C, Wunderlich M, Abdulrahim M, Goodwin TE, Hilinski G, Bennett CE, Hertlein E, Byrd JC. Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia. JCI Insight. 2024 Apr 22;9(8):e173646. PMID: 38646934.
Davids MS, Sharman JP, Ghia P, Woyach JA, Eyre TA, Jurczak W, Siddiqi T, Miranda P, Shahkarami M, Butturini A, Emeribe U, Byrd JC. Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials. Blood Adv. 2024 Jul 9;8(13):3345-3359. PMID: 38640349.
Woyach JA, Perez Burbano G, Ruppert AS, Miller C, Heerema NA, Zhao W, Wall A, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Stephens DM, Brown JR, Lozanski G, Blachly J, Nattam S, Larson RA, Erba H, Litzow M, Luger S,
Owen C, Kuzma C, Abramson JS, Little RF, Dinner S, Stone RM, Uy G, Stock W, Mandrekar SJ, Byrd JC. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024 Apr 18;143(16):1616-1627. PMID: 38215395.
Woyach JA, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, Eathiraj S, Reiff SD, Muhowski EM, Granlund L, Szuszkiewicz L, Wang W, Schwartz B, Ghori R, Farooqui MZH, Byrd JC. First-in-Human Study of the Reversible BTK Inhibitor
Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma. Cancer Discov. 2024 Jan 12;14(1):66-75. PMID: 37930156.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA,
Ferrant E, Wierda WG, Munugalavadla V, Yu T, Wang MH, Byrd JC. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-
naïve chronic lymphocytic leukemia. Leukemia. 2022 Apr;36(4):1171-1175. 2025 Feb;39(2):529. PMID: 34974526.
- Elected member, National Academy of Medicine, 2025
- Excellence in Scientific Service Award, Blood Cancer United, 2025